日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genomic Therapy Matching in Rare and Refractory Cancers

罕见和难治性癌症的基因组治疗匹配

Lin, Frank P; Thavaneswaran, Subotheni; Grady, John P; Napier, Christine E; Kansara, Maya; Sebastian, Lucille; Kee, Damien; Desai, Jayesh; Zaheed, Milita; Chinchen, Sarah; Oakes, Samantha R; Blackburn, James; Scott, Hamish S; Glover, Anthony; Fox, Stephen B; Goldstein, David; Leo, Paul; Amanuel, Benhur; Mersiades, Antony; Millward, Michael; Brown, Michael P; Charakidis, Michail; Pokorny, Adrian M J; Craft, Paul; Espinoza, David; Grimison, Peter; Harrup, Rosemary; Joshua, Anthony M; O'Byrne, Ken; Lee, Chee Khoon; Cowley, Mark J; Ballinger, Mandy L; Simes, John; Thomas, David M

Heterogeneity of treatment effect? What baseline prognostic factors tell us about immunotherapy benefit

治疗效果的异质性?哪些基线预后因素能告诉我们免疫疗法的益处

Lee, Chee Khoon; Simes, R John

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer

达到缓解所需时间和肿瘤最大缓解深度可作为晚期非小细胞肺癌总生存期的潜在替代指标

Woodford, Rachel; Lord, Sally; John, Tom; Yang, James Chih-Hsin; Simes, John; Marschner, Ian; Lee, Chee Khoon

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

奥拉帕尼、度伐利尤单抗和环磷酰胺联合预后血液特征治疗铂敏感卵巢癌:一项随机 II 期 SOLACE2 试验

Chee Khoon Lee ,Apriliana E R Kartikasari # ,Nirashaa T Bound # ,Katherine E Francis ,Kristy Shield-Artin ,Justin Bedo ,Ksenija Nesic ,Katrina Diamante ,Rachel L O'Connell ,Mutsa Madondo ,Momodou Cox ,Claire Davies ,Cyril Deceneux ,Georgia Goodchild ,Andrew Jarratt ,Emily Cassar ,Hina Amer ,U G Imalki U Kariyawasam ,Yeh Chen Lee ,Janine Lombard ,Sally Baron-Hay ,Yoland Antill ,Catherine Shannon ,Sudarshan Selva-Nayagam ,Philip Beale ,Danka Zebic ,Sandy Simon ,Anneliese Linaker ,Michael A Quinn ,Anthony T Papenfuss ,Matthew J Wakefield ,Cassandra J Vandenberg ,Michael Friedlander # ,Clare L Scott # ,Magdalena Plebanski #

Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion

亚洲地区IV期EGFR突变型非小细胞肺癌管理优化:专家意见

Chang, Gee-Chen; Kapoor, Akhil; Lee, Chee Khoon; Su, Chunxia; Chan, Daniel; Ladrera, Guia Elena Imelda; Kim, Hye Ryun; Sumon, Mostafa Aziz; Suryavanshi, Moushumi; Andarini, Sita; Yoshida, Tatsuya; Reungwetwattana, Thanyanan; Nguyen, Tuan Khoi; Voon, Pei Jye

Under the radar-frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies

癌症治疗临床试验中低级别不良事件的低频次、发生时间、持续时间和发展轨迹——鲜为人知的现象

Francis, Katherine E; Lord, Sarah J; Simon, Sandy; Friedlander, Michael; Gebski, Val; Simes, John; Lee, Chee Khoon

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab、Tremelimumab 和铂类化疗治疗 EGFR 突变阳性非小细胞肺癌:一项开放标签 2 期试验 (ILLUMINATE)

Lee, Chee Khoon; Liao, Bin-Chi; Subramaniam, Shalini; Chiu, Chao-Hua; Mersiades, Antony J; Ho, Chao-Chi; Brown, Chris; Lai, Chun-Liang; Hughes, Brett G M; Yang, Tsung-Ying; O'Byrne, Ken; Luo, Yung-Hung; Yip, Sonia; Ho, Ching-Liang; Bray, Victoria; Su, Wu-Chou; Moore, Melissa; Feng, Wei-Lien; Bai, Ya-Ying; Ford, Kate; Cummins, Michelle M; Stockler, Martin R; Solomon, Benjamin J; John, Thomas; Chih-Hsin Yang, James

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

FLAURA2 研究结果的简明摘要:奥希替尼一线治疗(联合或不联合化疗)在未经治疗的 EGFR 突变晚期非小细胞肺癌患者中的疗效

Planchard, David; Jänne, Pasi A; Cheng, Ying; Yang, James Chih-Hsin; Yanagitani, Noriko; Kim, Sang-We; Sugawara, Shunichi; Yu, Yan; Fan, Yun; Geater, Sarayut Lucien; Laktionov, Konstantin; Lee, Chee Khoon; Valdiviezo, Natalia; Ahmed, Samreen; Maurel, Jean-Marc; Andrasina, Igor; Goldman, Jonathan; Ghiorghiu, Dana; Rukazenkov, Yuri; Todd, Alex; Kobayashi, Kunihiko

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer

FLAURA2 研究结果的简明语言摘要:一线奥希替尼联合化疗对 EGFR 突变晚期非小细胞肺癌患者脑部的影响

Jänne, Pasi A; Planchard, David; Kobayashi, Kunihiko; Cheng, Ying; Lee, Chee Khoon; Valdiviezo, Natalia; Laktionov, Konstantin; Yang, Tsung-Ying; Yu, Yan; Kato, Terufumi; Jiang, Liyan; Chewaskulyong, Busyamas; Geater, Sarayut Lucien; Maurel, Jean-Marc; Rojas, Carlos; Takahashi, Toshiaki; Shepherd, Frances A; Tanaka, Kentaro; Ghiorghiu, Dana; Amin, Neha P; Armenteros-Monterroso, Elena; Huang, Xiangning; Ahmed Chaudhry, Ammar; Yang, James Chih-Hsin

Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians

亚太地区晚期肺癌治疗、医患联盟、癌症污名化和心理社会支持:来自患者、护理人员和医生的视角

Lee, Chee Khoon; Yang, Xue; Goto, Yasushi; Lee, Kang Yun; Yim, Hyung Seok; Brooke, Mark; Aoshima, Hisakazu; Ando, Emiko; Liu, Yiting; Tsai, Jane; Low, Grace Kah Mun; Kishiwada, Naomi; Cheng, Simone Marie; Rajendran, Divashini; Gowindah, Regina; Mon, Soe Pwint Phoo; Hong, Min Hee